大湖水殖股份有限公司 董事会薪酬与考核委员会实施细则 第一章 总则 第一条 为建立健全大湖水殖股份有限公司（以下简称"公司"）董事 及高级管理人员的薪酬和考核管理制度，完善公司治理结构，根据《中华 人民共和国公司法》（以下简称"公司法"）、《上市公司治理准则》、《上市 公司独立董事管理办法》等法律法规及《大湖水殖股份有限公司章程》（以 下简称"公司章程"）的规定，公司特设董事会薪酬与考核委员会，并制定 本实施细则。 第二条 薪酬与考核委员会是董事会设立的专门工作机构，主要负责制 定公司董事及高级管理人员的考核标准并进行考核；负责制定、审查公司 董事及高级管理人员的薪酬政策与方案，对董事会负责。 第三条 本实施细则所称董事是指在本公司支取薪酬的董事，高级管理 人员是指董事会聘任的总经理、副总经理、董事会秘书及由总经理提请董 事会认定的其他高级管理人员。 第二章 人员组成 第四条 薪酬与考核委员会成员由 3 名董事组成，其中独立董事应当过 半数。 第五条 薪酬与考核委员会委员由董事长、二分之一以上独立董事或者 全体董事的三分之一以上提名，并由董事会选举产生。 第六条 薪酬与考核委员会设主任委员（召集人）一名，应当 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥282,731,220.16, a decrease of 1.99% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was ¥13,501,914.25, down 20.19% year-on-year[5]. - The basic earnings per share for Q3 2023 was ¥0.0281, reflecting a decline of 20.29% compared to the previous year[6]. - Total revenue for the first three quarters of 2023 reached ¥872,830,730.71, an increase of 5.5% compared to ¥828,096,797.74 in the same period of 2022[23]. - Net profit for the first three quarters of 2023 was ¥20,108,652.59, compared to ¥6,695,268.38 in the same period of 2022, indicating a significant increase of 200.4%[24]. - The company reported a total comprehensive income of ¥24,142,231.35 for the first three quarters of 2023, compared to ¥6,695,268.38 in 2022, reflecting a substantial increase[25]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,130,420,889.75, a decrease of 1.46% from the end of the previous year[6]. - The company's total liabilities decreased to ¥1,105,248,241.07 from ¥1,160,504,202.31, a reduction of approximately 4.8%[20]. - The total equity attributable to shareholders increased to ¥886,103,842.34 from ¥879,723,654.23, showing a growth of 0.4%[20]. - The company's total liabilities as of September 30, 2023, included short-term borrowings of RMB 298,818,489.44, an increase from RMB 263,806,070.52 at the end of 2022[18]. - The company's non-current assets totaled RMB 1,146,973,590.55, down from RMB 1,208,517,210.36 at the end of 2022, reflecting a decrease of approximately 5.09%[18]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥42,837,061.53, an increase of 154.00% compared to the same period last year[10]. - The net cash flow from operating activities for the first three quarters of 2023 was ¥42,837,061.53, significantly up from ¥16,864,970.89 in the first three quarters of 2022[28]. - The total cash inflow from investment activities in the first three quarters of 2023 was ¥27,306,994.00, a decrease of 74.9% from ¥108,669,938.52 in the same period of 2022[29]. - The net cash flow from financing activities for the first three quarters of 2023 was ¥10,525,553.59, recovering from a negative cash flow of -¥43,220,571.46 in the same period of 2022[29]. - The company experienced a net increase in cash and cash equivalents of ¥57,112,995.99 in Q3 2023, contrasting with a net decrease of -¥74,389,449.15 in Q3 2022[29]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 71,516[12]. - The company’s major shareholder, Tibet Hongshan Technology Development Co., Ltd., holds 104,631,211 shares, representing 21.74% of total shares[14]. - The company reported a total of 13,953,762 shares held by shareholder Fan Yuanlong, accounting for 2.90% of total shares[14]. Operational Changes - The company reported a significant increase in prepayments by 46.38%, attributed to increased sales of frozen products[10]. - The company experienced a 58.40% rise in other receivables due to the transfer of equity in a subsidiary[10]. - The company’s subsidiary, Hunan Xiangyun Biotechnology Co., Ltd., filed for bankruptcy reorganization on July 5, 2023, resulting in the loss of financial and operational control over it[15]. Research and Development - Research and development expenses for the first three quarters of 2023 were ¥840,711.32, up from ¥754,558.28 in 2022, marking an increase of 11.4%[23].

证券代码：600257 证券简称：大湖股份 公告编号：2023-064 大湖水殖股份有限公司 关于参加 2023 年湖南辖区上市公司 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，使广大投资者能更深入 全面地了解大湖水殖股份有限公司（以下简称“公司”）情况，公 司将参加由湖南证监局、湖南省上市公司协会和深圳市全景网络 有限公司联合举办的“推动上市公司规范运作，保护中小投资者 ——2023 年湖南辖区上市公司投资者网上集体接待日“活动，现 将有关事项公告如下： 本次活动将采用“网络远程”的方式举行，投资者可登录“全 景路演”网站（https://rs.p5w.net），或关注微信公众号：全景 财经，或下载全景路演 APP，参与本次互动交流，活动时间为 2023 年 11 月 2 日（星期四）下午 14:00 至 17:00。届时公司高管将在 线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资 ...

证券代码：600257 证券简称：大湖股份 公告编号：2023-063 大湖水殖股份有限公司 | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 大湖水殖股份有限公司（以下简称"公司"）及下属子公司自 2023 年 1 月 1 日至 2023 年 10 月 25 日，收到与收益相关的政府补助 合计 7,716,415.96 元。现将相关情况公告如下： | 序 | 收款单位名称 | | 收到补助的时间 | | 发放主体 | 补助金额（元） | 补助原因/ | 补助依据 | 补助类型 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | | | | | | 项目 | | | | | 湖南湘云生物 | | | | 常德市就业服务 | | 留工培训 | | | | 1 | 科技有限公司 | 2023 年 1 | 月 3 日 | | 中心失业保险服 | 9,500.00 | 补助 | | 与收益相关 | | | | | | | 务所 ...

上 海 证 券 交 易 所 上证公监函〔2023〕0214 号 关于对大湖水殖股份有限公司 及有关责任人予以监管警示的决定 当事人： 大湖水殖股份有限公司，A 股证券简称：大湖股份，A 股证券代 码：600257； 戴兴华，大湖水殖股份有限公司时任财务总监。 经查明，大湖水殖股份有限公司（以下简称公司）在信息披露 方面，有关责任人在职责履行方面存在以下违规行为。 一、关联交易未履行审议程序及信息披露义务 2023 年 7 月 22 日，公司披露《关于补充确认关联交易的公告》， 补充认定部分关联方以及对部分历史关联交易补充履行审议及披露 程序，涉及 2020-2022 年度发生的采购和销售交易合计金额分别为 1,708.41 万元、2,813.70 万元、2,901.91 万元，占公司最近一期经 审计净资产之比分别为 1.47%、2.42%、3.06%。其中，公司 2021-2022 年度与补充认定的关联方分别开展关联交易 152.07 万元、597.35 万元，2020-2022 年度与其他关联方分别开展前期未预计的关联交易 1708.41 万元、2661.62 万元、2304.56 万元。上述金额达到董事会 ...

证券代码：600257 证券简称：大湖股份 公告编号：2023-062 大湖水殖股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性 承担个别及连带责任。 重要内容提示： ●根据《上海证券交易所上市公司自律监管指南第 1 号——公 告格式（2023 年 4 月修订）》的规定，大湖水殖股份有限公司（以 下简称"公司"）对 2023 年年度预计担保额度范围内的担保进展情 况按月度进行汇总披露。 ●本月新增实际提供担保金额共计为人民币 6,000 万元。 ●截止本公告披露日，公司在 2023 年年度预计担保额度范围内 为下属子公司已实际提供的担保余额为 20,120 万元（含本月新增担 保），占公司最近一期经审计的净资产的比例为 22.87%。 ●在本次披露的 2023 年年度预计担保额度范围内的担保进展中， 新签担保协议不涉及反担保。 ●截止本公告披露日，公司无对外担保逾期情况。 一、年度担保预计情况概述 公司于 2023 年 1 月 19 日召开的第八届董事会第二十六次会议 和 2023 年 2 月 6 ...

关于控股子公司东方华康医疗管理有限公司 2023 年 1 月至 9 月主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 一、控股子公司 2023 年 1 月至 9 月的主要经营数据 2023 年 1 月至 9 月，经公司财务部初步测算，大湖水殖股份有 限公司（以下简称"公司"）控股子公司东方华康医疗管理有限公司 （以下简称"东方华康"）预计实现营业收入约 2 亿元，较去年同期 增长约 23%；预计实现净利润约 5,000 万，较去年同期增长约 130%。 其中无锡国济康复医院与无锡国济护理院预计实现营业收入约 6,200 万元，较去年同期增长约 45%；预计实现净利润约 1,400 万元，去年 同期为亏损 534 万元。 东方华康 2023 年 1-9 月预计业绩增长，主要是由于 2023 年全国 经济逐渐恢复，市场有所回暖，业务拓展渠道放开所致，发展态势较 好。 证券代码：600257 证券简称：大湖股份 公告编号：2023-061 大湖水殖股份有限公司 本次公司控股子公司主要经营数据预计系公司财务 ...

证券代码：600257 证券简称：大湖股份 公告编号：2023-060 大湖水殖股份有限公司 ●投资者可于 2023 年 09 月 12 日(星期二)至 09 月 18 日(星期 一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 925286482@qq.com 进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 大湖水殖股份有限公司（以下简称"公司"）已于 2023 年 8 月 31 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地 了解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 09 月 19 日下午 15:00-16:30 举行 2023 年半年度业绩说明会，就投 资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2023 年半年度经营成果及财务指标的具体情况与投资者进行互动交流和 沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导 ...

公司于 2023 年 8 月 31 日收到西藏泓杉通知，西藏泓杉将其持有 本公司的部分股票解除质押，具体情况如下： 证券代码：600257 证券简称：大湖股份 公告编号：2023-059 大湖水殖股份有限公司 关于控股股东部分股票解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 重要内容提示： ●西藏泓杉科技发展有限公司（以下简称"西藏泓杉"）持有大 湖水殖股份有限公司（以下简称"公司"或"本公司"）104,631,211 股股票，占本公司总股本的比例为 21.74%，是公司的控股股东。本 次部分股票解除质押后，西藏泓杉累计质押股票 28,840,000 股，占 其所持有本公司股数的比例为 27.56%,占本公司总股本的比例为 5.99%。 一、上市公司部分股份解除质押 2023 年 9 月 1 日 | 股东名称 | 西藏泓杉 | | --- | --- | | 本次解除质押股份 | 22,500,000 股 | | 占其所持股份比例 | 21.50% | | 占公司总股本比例 | 4.68% | | 解 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately RMB 590.1 million, representing a 9.35% increase compared to RMB 539.6 million in the same period last year[20]. - The net profit attributable to shareholders of the listed company was a loss of approximately RMB 11.2 million, an improvement of 21.63% from a loss of RMB 14.2 million in the previous year[20]. - The basic earnings per share for the first half of 2023 was a loss of RMB 0.0232, an improvement of 22.99% from a loss of RMB 0.0301 in the same period last year[22]. - The company reported a total non-operating loss of 5,791,143.24, with significant impacts from minority interests and income tax adjustments[25]. - The company’s total revenue for the first half of 2023 was approximately CNY 590.1 million, representing a 9.35% increase compared to CNY 539.6 million in the same period last year[56]. - The company’s total comprehensive income for the first half of 2023 was -¥3,954,115.16, compared to -¥12,408,701.60 in the same period of 2022, indicating a significant reduction in comprehensive losses[127]. - The company reported a net asset value of 29.8032 million RMB for Dehai Medical Trade as of May 31, 2023[68]. - The company reported a total comprehensive income loss of 13,153,407.74 RMB for the first half of 2023[146]. Cash Flow and Assets - The net cash flow from operating activities was a negative RMB 69.3 million, which is a 33.32% improvement compared to a negative RMB 104.0 million in the same period last year[21]. - The total assets at the end of the reporting period were approximately RMB 2.11 billion, down 2.37% from RMB 2.16 billion at the end of the previous year[21]. - The total current assets as of June 30, 2023, amounted to ¥931,588,701.29, a decrease from ¥953,359,108.68 as of December 31, 2022, reflecting a decline of approximately 2.5%[116]. - Cash and cash equivalents decreased to ¥164,576,512.30 from ¥231,449,101.93, representing a decline of about 29%[116]. - The company’s total liabilities for Hangzhou Jincheng were reported at 167.55 million RMB[69]. - The total liabilities decreased from ¥1,160,504,202.31 to ¥1,113,743,822.07, a decline of about 4.03%[118]. - The total fair value of financial assets at the end of the period was 157,214,052.3 RMB, with a decrease of 668,359.74 RMB during the period[65]. Operational Segments and Strategies - The company operates in two main segments: health product production and sales, and health medical services, focusing on the synergy between these two areas[26]. - The aquaculture segment emphasizes a full industry chain model, including seed breeding, ecological farming, professional fishing, deep processing, and sales, supported by a flexible logistics supply chain[27]. - The company aims to expand its rehabilitation and nursing services across the Yangtze River Delta, targeting various demographics including the elderly and patients[28]. - The company is positioned to benefit from government initiatives supporting the development of modern facilities in aquaculture and cold chain logistics[32]. - The company’s strategy includes leveraging modern technology to enhance aquaculture efficiency and expand production capacity[31]. - The company aims to transform into a comprehensive health industry by integrating health products and services, optimizing its processing chain, and expanding sales channels[46]. Market Trends and Growth Potential - The pre-prepared dishes market in China is expected to exceed 800 billion yuan by 2025, with the market for sauerkraut fish pre-prepared dishes projected to reach 1.69 billion yuan, indicating significant growth potential in the sector[37]. - The rehabilitation medical market in China is projected to exceed 220 billion yuan by 2025, driven by an aging population and increasing rehabilitation needs[41]. - The aquatic product processing industry is characterized by low concentration, with only 31.28% of total aquatic product output being processed, suggesting a broad future development potential[36]. - The demand for pre-prepared aquatic dishes is becoming a new growth point in the aquatic product industry, driven by changing consumer habits and the rise of the "stay-at-home" economy[37]. - The white liquor industry is experiencing a structural adjustment with a shift towards high-quality development, supported by multiple industry policies aimed at standardization and quality improvement[39]. Research and Development - Research and development expenses surged by 105.27%, reaching CNY 402,439.14 compared to CNY 196,052.02 in the previous year[56]. - The company has made substantial progress in research and development, achieving breakthroughs in fish breeding and processing technologies, which will support future production capabilities[45]. - The company has received significant awards for its technological innovations in aquaculture, including first-class awards for key technology research in freshwater fish processing[45]. Corporate Governance and Structure - The company appointed several new executives, including a new chairman and multiple vice presidents, during the recent board restructuring[75]. - The company has not disclosed any employee stock ownership plans or other incentive measures during the reporting period[78]. - The company has not reported any changes in its controlling shareholder or actual controller during the reporting period[112]. - The total number of ordinary shareholders as of the end of the reporting period is 53,393[106]. Sustainability and Social Responsibility - The company is committed to sustainable practices in aquaculture, aligning with national environmental protection initiatives to ensure ecological balance[47]. - Total donations for rural revitalization and poverty alleviation projects amounted to CNY 121,800, with CNY 100,000 donated to Yanglouping Village and CNY 21,800 for organic fertilizer[81]. - The company adopts an ecological breeding model for fish farming, which aligns with national green development initiatives[80].